The mechanisms of drug resistance are under intensive study and include an adaptive response whereby MAPK signaling is reactivated in tumor cells despite continuous exposure to BRAF inhibitors (Lito et al, 2012, 2013; Shi et al, 2012). The gene discussed is BRAF; the disease is neoplasm.